12 June 2026
Latham & Watkins Advises Hercules Capital in an Up to US$300 Million Growth Financing for Leading Biotech Beren Therapeutics
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Todd Trattner Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Hai Pham Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| William Lane | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Jake Ibrahim | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Sam Yang | Latham & Watkins LLP | Associate | tax | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 300m (US$300 million)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- Beren Therapeutics P.B.C. (Borrower)
Hercules Capital, Inc. (Lenders)